Concepedia

Author

Michael McCleod

Florida Cancer Specialists & Research Institute

Also Known As

M McCleod, M. J. McCleod, M. McCleod, M. Mccleod, M.J. McCleod, Michael J. McCleod, Michael J. Mccleod, Michael McCleod, Michael Mccleod

59

Publications

4.5K

Citations

20

H-Index

35

Concepts

All Affiliations

Florida Cancer Specialists & Research InstituteSarah CannonTennessee OncologyOncology Hematology CareFlorida Hospital Cancer Institute
MM

About

Michael McCleod is an author at Florida Cancer Specialists & Research Institute specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

16

20

2.8K

2

Health Sciences

3

3

505

3

Engineering

1

1

13

4

Biomedical Engineering

1

1

13

5

Cell Biology

1

1

74

Michael McCleod

×

29

Publications

4.4K

Citations

19

H-Index

YearCitations

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

Howard West, Michael McCleod, Maen Hussein,

The Lancet Oncology

2019

1.6K

Addition of Bevacizumab to Bolus Fluorouracil and Leucovorin in First-Line Metastatic Colorectal Cancer: Results of a Randomized Phase II Trial

Fairooz F. Kabbinavar, Joseph J. Schulz, Michael McCleod,

Journal of Clinical Oncology

2005

932

Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099

Thomas J. Lynch, Taral Patel, Luke Dreisbach,

Journal of Clinical Oncology

2010

447

Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153

David Waterhouse, Edward B. Garon, Jason C. Chandler,

Journal of Clinical Oncology

2020

223

Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non–Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153)

David R. Spigel, Michael McCleod, Robert M. Jotte,

Journal of Thoracic Oncology

2019

184

ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer

David Planchard, Niels Reinmuth, Jürgen R. Fischer,

Annals of Oncology

2020

156

A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study

David Planchard, Takashi Yokoi, Michael McCleod,

Clinical Lung Cancer

2016

129

B3-03: A randomized multicenter phase III study of cetuximab (Erbitux®) in combination with Taxane/Carboplatin versus Taxane/Carboplatin alone as first-line treatment for patients with advanced/metastatic Non-small cell lung cancer (NSCLC)

Thomas J. Lynch, Taral Patel, Luke Dreisbach,

Journal of Thoracic Oncology

2007

84

A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive‐disease small cell lung cancer

Ravi Salgia, John R. Stille, R Weaver,

Lung Cancer

2017

74

IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC

Federico Cappuzzo, Michael McCleod, Maen Hussein,

Annals of Oncology

2018

58

Page 1